Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Bavarian Nordic reports Phase III data for smallpox vaccine
Jynneos vaccine has been assessed in a comprehensive development programme of 22 clinical trials. Credit: Bavarian Nordic.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
Close
-
Malvern Panalytical
Malvern Panalytical offers characterisation tools for molecular analysis and small...
About
Malvern Panalytical offers characterisation tools for molecular analysis and small drug discovery to help accelerate development for the pharmaceutical industry.
FollowMake an Enquiry
-
Pilloxa
Pilloxa creates digital and remote solutions to optimise clinical trials...
About
Pilloxa creates digital and remote solutions to optimise clinical trials and patient support programmes through supporting medical adherence and patient retention.
FollowMake an Enquiry
-
SOM Biotech
SOM Biotech is an Artificial Intelligence AI drug discovery and...
About
SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
FollowMake an Enquiry